Pioglitazone: Reports of its death are greatly exaggerated - it is alive and ready to resume saving lives

Diabetic Medicine

Volumn 32, Issue 4, 2015, Pages e9-e15

  Ryder, R E J ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CARCINOGEN;

ARTICLE; BLADDER CANCER; CANCER RISK; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; HEMATURIA; HUMAN; LUNG CANCER; META ANALYSIS (TOPIC); NONHUMAN; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR PROMOTION; URINALYSIS; ANIMAL; DIABETIC ANGIOPATHIES; DRUG RECALL; OBSERVATIONAL STUDY; RAT; RISK FACTOR; URINE;

ANIMALS; CARCINOGENS; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RISK FACTORS; SAFETY-BASED DRUG WITHDRAWALS; THIAZOLIDINEDIONES; URINE;

EID: 84924690366     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12736     Document Type: Article

References (26)

1. Mark Twain and Steve Jobs were both great men who were victims of the publishing of a premature obituary. The original quote by Mark Twain in response to a premature obituary was 'the report of my death was an exaggeration' (see http://en.wikiquote.org/wiki/Mark_Twain Last accessed 22 December 2014). Often misquoted as 'The reports of my death are greatly exaggerated' including by Steve Jobs (see http://en.wikipedia.org/wiki/Steve_Jobs Last accessed 22 December 2014) when he was also the recipient of a premature obituary.
2. Ryder REJ. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet Med 2015; 32: 305-313.
3. Gale EAM. Pioglitazone: are rumours of its death exaggerated? Diabet Med 2015; 32: 431-437.
4. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
6. Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig 2013; 33: 621-631.
7. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16: 1065-1071.
8. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168: 2368-2375.
9. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-418.
10. European Medicines Agency. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact (INN: Pioglitazone, pioglitazone+glimepiride, pioglitazone+metformin) 22 December 2011 (EMA, CHMP/940059/2011). Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000285/WC500126656.pdf Last accessed 23 December 2014.
11. Dormandy J, Bhattacharya M, devan Troostenburg Bruyn AR. PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187-202.
12. Lewis JD, Ferrara A, Strom BL, Quesenberry CPJr, Bilker WB, Peng T et al. Cohort Study of Pioglitazone and Bladder Cancer in Patients with Diabetes: Fourth Interim Analysis (8-Year) Report with Data from January 1, 1997 to December 31, 2010. May 30, 2012. Available at http://general.takedapharm.com/Trial-Disclosure/01-03-TL-OPI-524-8-year-Interim-Report.pdf Last accessed 23 December 2014.
13. Lewis JD, Habel L, Quesenberry C, Mamtani R, Peng T, Bilker WB et al. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf 2014; 23: 636-645.
14. Lewis JD, Ferrara A, Strom BL, Quesenberry CPJr, Bilker WB, Peng T et al. KPNC 4th Interim Report, Cohort Study of Pioglitazone and Bladder Cancer (Study No. 01-03-TL-OPI-524) FDA advice/information request for sensitivity analysis and other analyses. Available at http://www.encepp.eu/encepp/openAttachment/documents.otherDocument-1/3652;jsessionid=P5CbTb3YKHyR2R20g217NK12hX2yX1TS1fQjbGn2x40HWqcy1PQt!1684841325 Last accessed 23 December 2014.
15. Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, Usuda N et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001; 159: 591-597.
16. Takeda Pharmaceutical Company Limited. Actos (pioglitazone hydrochloride). US package insert. Osaka: Takeda, 2004 Aug.
17. Turner RM, Kwok CS, Chen-Turner C, Maduakar CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014; 78: 258-273.
18. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Can Med Assoc J 2012; 184: E675-E683.
19. He S, Tang Y, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumor Biol 2014; 35: 2095-2102.
20. Takeda Pharmaceutical Company Limited. Data on file. Kindly supplied through personal communication from Dr Alfonso Perez, VP Clinical Science, Takeda Pharamaceauticals, 18 December 2014; updated 22 January 2015.
21. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
22. Reaven G. Insulin resistance, hypertension, and coronary heart disease. J Clin Hypertens 2003; 5: 269-274.
23. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
24. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383.
25. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2014; doi: 10.1007/s00125-014-3456-9 [Epub ahead of print].
26. Pioglitazone and bladder cancer. A letter from the Association of British Clinical Diabetologists (ABCD) to the Medicines and Healthcare Products Regulatory Agency (MHRA). 17 June 2011. Available at http://www.diabetologists-abcd.org.uk/Shared_Documents/position_papers/ABCD_pioglitazone_submission_to_MHRA.pdf Last accessed 24 December 2014.